I agree that this site is using cookies. You can find further informations here.
X
Usmani, SZ
30  results:
Search for persons X
?
1

EE167 Use of Cost per Responder Models for CAR-T Therapies ..:

Martin, T ; Usmani, SZ ; Joseph, N...
Value in Health.  25 (2022)  7 - p. S366 , 2022
Link: https://doi.org/10.1016/..
 
?
2

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS..:

Dimopoulos, MA ; Oriol, A ; Nahi, H...
HemaSphere.  6 (2022)  - p. 13-13 , 2022
Link: https://doi.org/10.1097/..
 
?
3

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUM..:

Mateos, M ; Hari, P ; Bahlis, N...
HemaSphere.  6 (2022)  - p. 9-9 , 2022
Link: https://doi.org/10.1097/..
 
?
4

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEU..:

Gay, F ; Berdeja, JG ; De Stefano, V...
HemaSphere.  6 (2022)  - p. 8-8 , 2022
Link: https://doi.org/10.1097/..
 
?
5

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGEN..:

Usmani, SZ ; Berdeja, JG ; Jakubowiak, A...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S272 , 2021
Link: https://doi.org/10.1016/..
 
?
6

Rates of Influenza and Pneumococcal Vaccination and Correla..:

Thompson, MA ; Boccadoro, M ; Leleu, X...
https://eprints.whiterose.ac.uk/195853/6/Rates%20of%20Influenza%20and%20Pneumococcal%20Vaccination%20and%20Correlation%20With%20Survival%20in%20Multiple%20Myeloma%20Patients.pdf.  , 2023
Link: https://eprints.whiteros..
 
?
7

Final analysis of the phase III non-inferiority COLUMBA stu..:

Usmani, SZ ; Nahi, H ; Legiec, W...
Haematologica: the hematology journal, 2022,.  , 2022
Link: https://repository.icr.a..
 
?
8

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEU..:

Gay, F ; Berdeja, JG ; De Stefano, V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009793/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
9

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS..:

Dimopoulos, MA ; Oriol, A ; Nahi, H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009798/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUM..:

Mateos, M ; Hari, P ; Bahlis, N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012119/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Perspectives on the Risk-Stratified Treatment of Multiple M..:

Davies, FE ; Pawlyn, C ; Usmani, SZ...
699310.  , 2022
Link: https://repository.icr.a..
 
?
12

Daratumumab plus lenalidomide and dexamethasone in transpla..:

Facon, T ; Cook, G ; Usmani, SZ...
issn:0887-6924.  , 2022
Link: http://hdl.handle.net/11..
 
?
13

Management of patients with multiple myeloma beyond the cli..:

Terpos, E ; Mikhael, J ; Hajek, R...
Blood cancer journal, 2021, 11 (2), pp. 40 - ?.  , 2021
Link: https://repository.icr.a..
 
?
14

Treatment of relapsed and refractory multiple myeloma: reco..:

Moreau, P ; Kumar, SK ; Miguel, JS...
https://discovery.ucl.ac.uk/id/eprint/10125552/1/IMWG_relapse_V6_AUGUST_8_2020.pdf.  , 2021
Link: https://discovery.ucl.ac..
 
?
15

Management of patients with multiple myeloma beyond the cli..:

Terpos, E ; Mikhael, J ; Hajek, R...
https://eprints.whiterose.ac.uk/171668/6/s41408-021-00432-4.pdf.  , 2021
Link: https://eprints.whiteros..
 
1-15